A feasibility study using quantitative and interpretable histological analyses of celiac disease for automated cell type and tissue area classification.

Autor: Griffin M; PathAI, Inc., 1325 Boylston Street, Suite 10000, Boston, MA, 02215, USA., Gruver AM; Eli Lilly and Company, Indianapolis, IN, USA., Shah C; PathAI, Inc., 1325 Boylston Street, Suite 10000, Boston, MA, 02215, USA., Wani Q; PathAI, Inc., 1325 Boylston Street, Suite 10000, Boston, MA, 02215, USA., Fahy D; PathAI, Inc., 1325 Boylston Street, Suite 10000, Boston, MA, 02215, USA., Khosla A; PathAI, Inc., 1325 Boylston Street, Suite 10000, Boston, MA, 02215, USA., Kirkup C; PathAI, Inc., 1325 Boylston Street, Suite 10000, Boston, MA, 02215, USA., Borders D; PathAI, Inc., 1325 Boylston Street, Suite 10000, Boston, MA, 02215, USA., Brosnan-Cashman JA; PathAI, Inc., 1325 Boylston Street, Suite 10000, Boston, MA, 02215, USA., Fulford AD; Eli Lilly and Company, Indianapolis, IN, USA., Credille KM; Eli Lilly and Company, Indianapolis, IN, USA., Jayson C; PathAI, Inc., 1325 Boylston Street, Suite 10000, Boston, MA, 02215, USA., Najdawi F; PathAI, Inc., 1325 Boylston Street, Suite 10000, Boston, MA, 02215, USA. fedaa.najdawi@pathai.com., Gottlieb K; Eli Lilly and Company, Indianapolis, IN, USA.

Publikováno v: Scientific reports [Sci Rep] 2024 Dec 02; Vol. 14 (1), pp. 29883. Date of Electronic Publication: 2024 Dec 02.

Targeted Quantitative Mass Spectrometry Analysis of Protein Biomarkers From Previously Stained Single Formalin-Fixed Paraffin-Embedded Tissue Sections.

Autor: Ackermann BL; Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, Indiana., Morrison RD; Protypia, Inc, Nashville, Tennessee., Hill S; Protypia, Inc, Nashville, Tennessee., Westfall MD; Protypia, Inc, Nashville, Tennessee., Butts BD; Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, Indiana., Soper MD; Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, Indiana., Fill JA; Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, Indiana., Schade AE; Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, Indiana., Liebler DC; Protypia, Inc, Nashville, Tennessee. Electronic address: daniel.liebler@protypia.com., Gruver AM; Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, Indiana. Electronic address: gruver_aaron_m@lilly.com.

Publikováno v: Laboratory investigation; a journal of technical methods and pathology [Lab Invest] 2023 Apr; Vol. 103 (4), pp. 100052. Date of Electronic Publication: 2023 Jan 10.

Population-based estimate for the correlation of the Oncotype Dx Breast Recurrence Score® result and Ki-67 IHC MIB-1 pharmDx in HR+, HER2-, node-positive early breast cancer.

Autor: Crager M; Biostatistics - Exact Sciences Corporation, Redwood City, CA, USA., Wijayawardana SR; Global Statistical Sciences - Oncology, Eli Lilly and Company, Indianapolis, IN, USA., Gruver AM; Clinical Diagnostics Laboratory, Eli Lilly and Company, Indianapolis, IN, USA., Blacklock A; Medical - Exact Sciences, Redwood City, CA, USA., Russell C; Medical Affairs - Exact Sciences, Redwood City, CA, USA., Baehner FL; Medical - Exact Sciences, Redwood City, CA, USA., Sapunar F; Global Medical Affairs, Eli Lilly and Company, Basingstoke, UK. sapunar_francisco@lilly.com.; Lilly Corporate Center, Indianapolis, IN, 46285, USA. sapunar_francisco@lilly.com.

Publikováno v: Breast cancer research : BCR [Breast Cancer Res] 2022 Nov 01; Vol. 24 (1), pp. 74. Date of Electronic Publication: 2022 Nov 01.

Two Instrument Comparison of Reagents From a US FDA-Approved Assay for the Assessment of Ki-67 in High-Risk Early Breast Cancer.

Autor: Komforti M; Robert J. Tomsich Pathology & Laboratory Medicine Institute, Cleveland Clinic, Cleveland, OH., Downs-Kelly E; Robert J. Tomsich Pathology & Laboratory Medicine Institute, Cleveland Clinic, Cleveland, OH., Sapunar F; Global Medical Affairs, Eli Lilly and Company, Basingstoke, UK., Wijayawardana SR; Global Statistical Sciences - Oncology., Gruver AM; Clinical Laboratory Sciences, Eli Lilly and Company., Badve SS; Department of Pathology & Laboratory Medicine, Indiana University School of Medicine, Indianapolis IN.; Pathology & Laboratory Medicine, Emory University School of Medicine, Atlanta, GA.

Publikováno v: Applied immunohistochemistry & molecular morphology : AIMM [Appl Immunohistochem Mol Morphol] 2022 Sep 01; Vol. 30 (8), pp. 577-583. Date of Electronic Publication: 2022 Jul 27.

MET ectodomain shedding is associated with poor disease-free survival of patients diagnosed with oral squamous cell carcinoma.

Autor: De Herdt MJ; Department of Otorhinolaryngology and Head and Neck Surgery, Cancer Institute Erasmus MC, University Medical Center Rotterdam, Dr. Molewaterplein 40, 3015 GD, Rotterdam, The Netherlands., Koljenović S; Department of Pathology, Cancer Institute Erasmus MC, University Medical Center Rotterdam, Dr. Molewaterplein 40, 3015 GD, Rotterdam, The Netherlands., van der Steen B; Department of Otorhinolaryngology and Head and Neck Surgery, Cancer Institute Erasmus MC, University Medical Center Rotterdam, Dr. Molewaterplein 40, 3015 GD, Rotterdam, The Netherlands., Willems SM; Department of Pathology, University Medical Center Utrecht, Heidelberglaan 100, 3584 CX, Utrecht, The Netherlands., Noorlag R; Department of Oral and Maxillofacial Surgery, University Medical Center Utrecht, Heidelberglaan 100, 3584 CX, Utrecht, The Netherlands., Nieboer D; Department of Public Health, Erasmus MC, University Medical Center Rotterdam, Dr. Molewaterplein 40, 3015 GD, Rotterdam, The Netherlands., Hardillo JA; Department of Otorhinolaryngology and Head and Neck Surgery, Cancer Institute Erasmus MC, University Medical Center Rotterdam, Dr. Molewaterplein 40, 3015 GD, Rotterdam, The Netherlands., Gruver AM; Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, IN, USA., Zeng W; Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, IN, USA., Liu L; Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, IN, USA., de Jong RJB; Department of Otorhinolaryngology and Head and Neck Surgery, Cancer Institute Erasmus MC, University Medical Center Rotterdam, Dr. Molewaterplein 40, 3015 GD, Rotterdam, The Netherlands., Looijenga LH; Department of Pathology, Cancer Institute Erasmus MC, University Medical Center Rotterdam, Dr. Molewaterplein 40, 3015 GD, Rotterdam, The Netherlands. l.looijenga@erasmusmc.nl.; Princess Maxima Center for Pediatric Oncology, Heidelberglaan 25, 3584 CS, Utrecht, The Netherlands. l.looijenga@erasmusmc.nl.

Publikováno v: Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc [Mod Pathol] 2020 Jun; Vol. 33 (6), pp. 1015-1032. Date of Electronic Publication: 2019 Dec 19.